Clinical Trial Update: A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the anamnestic immune response in healthy children after a primary vaccination series with HEXAVAC or INFANRIX-Hexa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Hexavac (DTPa-HBV-IPV-Hib hexavalent vaccine)
• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED